Greenwich LifeSciences Inc

NASDAQ:GLSI   3:59:50 PM EDT
32.18
-0.92 (-2.78%)
Products, Regulatory

Greenwich Lifesciences Provides Clinical Update On Upcoming Phase Iii Clinical Trial, Flamingo-01

Published: 11/10/2021 12:18 GMT
Greenwich LifeSciences Inc (GLSI) - Greenwich Lifesciences Provides Clinical Update on Upcoming Phase Iii Clinical Trial, Flamingo-01.
Greenwich Lifesciences Inc - Gp2 Phase Iii Clinical Trial Will Be Called Flamingo-01 and Combination of Gp2 + Gm-csf Will Be Called Glsi-100.
Greenwich Lifesciences Inc - Currently Completing Last Steps to Release Glsi-100 Drug Product Vials to Clinical Sites and to Open Clinical Sites.